RSV can boost seniors' heart risks
The risk for heart failure was seen even in individuals without a history of heart problems, researchers reported in the Journal of the American Geriatrics Society.
The researchers reviewed data on more than 100,000 adults aged 65 and older hospitalized in Ontario between 2011 and 2020 for either RSV, influenza, urinary tract infection, or a fracture.
The proportion of patients with a subsequent cardiovascular event was 18.5% after an RSV-related hospitalization, compared to 17.7%, 12.1% and 8.4% after hospitalizations for influenza, urinary tract infection, or fracture, respectively.
In comparisons of patients who were closely matched according to demographics and risk factors, heart failure (10%-11%) was the most common outcome for RSV patients, occurring in 10% to 11%. Next most common was the heart rhythm disorder atrial fibrillation, occurring in 5% to 6% of RSV patients.
The risk for those outcomes, as well as for heart attack, "was at least two to three times higher in patients with a pre-existing cardiovascular condition compared to those without," the researchers also said.
"Our findings reinforce the importance of RSV vaccination in older adults and suggest that monitoring for signs of heart disease following an RSV illness may be pragmatic," study leader Chris Verschoor of Health Sciences North Research Institute in Sudbury, Ontario, said in a statement.
DYE TEST CAN HELP AVOID INTESTINE SURGERY
Sending dye through the small intestine to look for blockages has been sparing a significant proportion of patients from needing to undergo surgery, a new study shows.
The dye, Gastrografin from Bracco Diagnostics Inc., is administered to symptomatic patients before an X-ray or CT scan so that surgeons can see the location and severity of any so-called adhesive small bowel obstructions.
Researchers reviewed nationwide data on more than 20,000 patients with suspected small bowel obstruction managed in two periods - 2012 to 2016, before Gastrografin was widely used for this purpose, and 2019 to 2023, when using Gastrografin to visualize intestinal blockages was a standard of care.
They found nearly a 45% decrease in surgeries for small bowel obstruction in the Gastrografin era, from 13,257 to 7,333.
Small bowel obstruction accounts for 15% of hospital admissions in the U.S., with about 20% of cases needing surgery to reconstruct the intestine, the researchers said. The resulting healthcare costs total over $3 billion each year.
Despite better small bowel obstruction outcomes overall, post-surgery mortality increased from 4.4% to 5.9% after use of the dye became standard, and reoperations within 30 days rose from 4.7% to 6.2% - likely because surgeries were probably more complex in the later era, the researchers said.
Gastrografin testing had weeded out patients with relatively mild obstructions who ultimately didn't need surgery, they added.
"Previously, patients who had a relatively mild adhesive small bowel obstruction would have been operated on, as we didn't have an alternative option," study leader Dr. Robert McLoughlin from the University of Connecticut School of Medicine in Farmington said in a statement.
"This meant that in the post-Gastrografin era, the surgeries were more complex and challenging, hence the increased morbidity and mortality."
Still, because surgeons have gotten better at managing patients after surgery for small bowel obstructions, patients in the Gastrografin group averaged 6 days in the hospital, versus about 10 days for patients treated before the Gastrografin era, the researchers reported in the Journal of Surgical Research.
The current study was not designed to prove that any of the outcomes were the result of Gastrografin use, the article pointed out.
McLoughlin recalled that during a discussion with a younger colleague about managing small bowel obstructions, he mentioned that when he was in training, surgeons operated "on a lot more" of these patients.
That recollection prompted the current study, he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
The silent heart condition putting young adults at risk: What is Hypertrophic Cardiomyopathy, and what are the overlooked symptoms
On the surface, it all looks nice and shiny; energetic and unstoppable, even. However, a threat seems to be lurking around the corner and creeping up silently in the lives of young adults. What is it? It's called hypertrophic cardiomyopathy (HCM) . Often symptom-free and misunderstood, this genetic heart condition thickens the heart muscle, especially in the left ventricle, making it harder to pump blood and increasing the risk of dangerous heart rhythms and sudden cardiac death. And mistake not for its 'silent' nature, it can strike without warning. Characterized by thickened heart muscle, HCM reduces the heart's pumping efficiency and often hides behind vague symptoms like shortness of breath, fatigue, or fainting. Because many affected individuals are asymptomatic or misinterpret symptoms as stress or poor fitness, this condition often goes unnoticed until a serious event, such as sudden cardiac arrest. What Is Hypertrophic Cardiomyopathy? HCM is a genetic heart condition in which the heart muscle becomes abnormally thick, often impacting the wall between the pumping chambers, known as the septum. This thickening can narrow the pathway for blood to leave the heart (obstructive HCM) or simply make the heart stiffer and less able to fill and pump efficiently (non-obstructive HCM). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Remember Him? Sit Down Before You See What He Looks Like Now 33 Bridges Undo This increased muscle mass can also disturb the heart's electrical system, raising the risk of dangerous arrhythmias and, tragically, sudden cardiac death, even in otherwise healthy young people. While many people with HCM live normal lives, the condition is the leading cause of sudden cardiac death (SCD) among young athletes and active adults under 35. Why it's called the 'silent' heart condition Many individuals with HCM never experience noticeable symptoms ; some estimates suggest up to 50% may remain symptom-free or only mildly symptomatic. Others may dismiss faintness, chest tightness, or breathlessness as normal fatigue or stress. HCM is alarmingly common among young adults and athletes; studies show it's the leading cause of sudden cardiac death in young athletes, accounting for nearly one in four such cases. Why young adults are especially at risk Young people with undiagnosed HCM may seem perfectly healthy, but they experience hidden danger. Older research suggested mortality rates up to around 6% per year in children with HCM, often due to SCD. However, recent advancements in treatments such as implantable defibrillators (ICDs), targeted medications, and surgical options have improved outcomes dramatically. A study tracking nearly 500 patients aged 7 to 29 found a lower annual HCM-related death rate of about 0.5%, thanks to early intervention and modern treatment strategies. Furthermore, family history is a key clue. HCM is inherited in an autosomal dominant pattern, meaning a child has a 50% chance of inheriting it from an affected parent. Even elite athletes with no symptoms can suffer sudden cardiac arrest, as happened to high school wrestler J.J. at age 18 and an NBA player, Jared Butler, who learned of his diagnosis during a routine physical at 18 – cases that have drawn much attention to the 'silent' killer. Overlooked and subtle symptoms Many individuals with HCM don't experience obvious symptoms or may ignore them: Shortness of breath during exertion or even at rest Chest pain or angina-like discomfort during activity Heart palpitations, dizziness, or fainting episodes Fatigue, swelling in the legs or abdomen, and unusual lightheadedness These signs are often dismissed as stress, poor fitness, or non-serious ailments; delay in diagnosis is common. In some cases, sudden death is the first obvious indication of HCM. Screening and early detection: Why it matters Because HCM is often inherited in an autosomal dominant pattern, family history matters. Screening methods include listening for heart murmurs, plus diagnostic tools like ECG, echocardiograms, MRI, and genetic testing. Early treatment can slow or prevent disease progression. A clinical trial found that young adults treated early with valsartan (a blood pressure medication) showed reduced physical progression of HCM vs. placebo. Treatments of HCM While HCM can't be cured, it can be effectively managed. Management of HCM is likely to include: Medications like beta-blockers, calcium channel blockers, disopyramide, and the newer FDA-approved drug mavacamten. Implantable cardioverter-defibrillators (ICDs) for those at high risk of SCD. In severe cases, surgical interventions, like septal myectomy or alcohol septal ablation, can relieve obstruction. Shared decision-making with your medical team to tailor treatment based on your age, goals, and risk factors. Lifestyle changes, including avoiding vigorous competitive sports, can reduce risk and improve quality of life. Thanks to modern therapies, most individuals have a normal life expectancy and manage well with proper monitoring and support. Living with HCM: What you should do Be alert to subtle symptoms: don't brush off fainting, fatigue, or shortness of breath. Know your family's heart history: First-degree relatives should get screened. Get early and accurate testing if at risk: ECG, echo, MRI, and genetics can offer clarity. Work closely with your care team: Use shared decision-making to choose the best management path. Stay informed on new treatments: Medications like mavacamten and minimally invasive procedures offer promising options. The parting thought Hypertrophic cardiomyopathy is a silent, and often deadly, heart condition that hides behind normal activity, especially in the young and fit. But with awareness, screening, and early action, lives can be protected. If you or a loved one experiences unexplained breathlessness, fainting, chest pain, or palpitations, or has a family history of heart disease, talk to a doctor. A simple test could be the difference between tragedy and prevention. Catching HCM early can make it manageable, not deadly. How To Identify Heart Attack
Time of India
7 hours ago
- Time of India
AIIMS-R VRDL gets accreditation for diagnosis of 12 major viral infections
Raipur: The state viral research and diagnostic laboratory (VRDL) at the All India Institute of Medical Sciences (AIIMS), Raipur, has received its first accreditation from National Accreditation Board for Testing & Calibration Laboratories (NABL). The laboratory, which functions under the Department of Microbiology, was accredited for the diagnosis of 12 major viral infections. These include viral meningitis and encephalitis, COVID-19 (SARS-CoV-2), swine flu ( H1N1 ), influenza B, respiratory syncytial virus (RSV), and 14 high-risk human papillomavirus (HR-HPV) types that cause cervical cancer . The list also includes Epstein-Barr virus (EBV), Herpes simplex virus (HSV), cytomegalovirus (CMV), Hepatitis B and C viral load, and dengue. Established in 2018, the VRDL provides diagnostic services to patients at AIIMS Raipur and receives samples from across Chhattisgarh. It is involved in testing for COVID-19, Hepatitis A, B, C, E, and dengue. The lab also assists in investigating outbreaks of viral diseases like chickenpox, conjunctivitis, and mumps. The VRDL is the state nodal centre for COVID-19 testing , quality control, and whole genome sequencing of SARS-CoV-2. Lt Gen Ashok Jindal (Retd), Executive Director and CEO of AIIMS Raipur, congratulated the team for their achievement, stating that the NABL accreditation is a step towards national recognition for the diagnostic services provided to the people of Chhattisgarh. Prof Dr Anudita Bhargava, Head, Department of Microbiology, said the recognition was the result of teamwork and dedication by the entire staff.
Time of India
16 hours ago
- Time of India
AIIMS-R VRDL gets 1st NABL accreditation for diagnosis of 12 major viral infections
Raipur: The state viral research and diagnostic laboratory (VRDL) at the All India Institute of Medical Sciences (AIIMS), Raipur, has received its first accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL). The laboratory, which functions under the Department of Microbiology, was accredited for the diagnosis of 12 major viral infections. These include viral meningitis and encephalitis, COVID-19 (SARS-CoV-2), swine flu (H1N1), influenza B, respiratory syncytial virus (RSV), and 14 high-risk human papillomavirus (HR-HPV) types that cause cervical cancer. The list also includes Epstein-Barr virus (EBV), Herpes simplex virus (HSV), cytomegalovirus (CMV), Hepatitis B and C viral load, and dengue. Established in 2018, the VRDL provides diagnostic services to patients at AIIMS Raipur and receives samples from across Chhattisgarh. It is involved in testing for COVID-19, Hepatitis A, B, C, E, and dengue. The lab also assists in investigating outbreaks of viral diseases like chickenpox, conjunctivitis, and mumps. The VRDL is the state nodal centre for COVID-19 testing, quality control, and whole genome sequencing of SARS-CoV-2. Lt Gen Ashok Jindal (Retd), Executive Director and CEO of AIIMS Raipur, congratulated the team for their achievement, stating that the NABL accreditation is a step towards national recognition for the diagnostic services provided to the people of Chhattisgarh. Prof Dr Anudita Bhargava, who heads the Department of Microbiology, said the recognition was the result of teamwork and dedication by the entire staff. Prof. Dr Sanjay Singh Negi stated that the accreditation, which follows the ISO 15189:2022 standards, reflects the high quality of the diagnostic testing. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
